294 related articles for article (PubMed ID: 9647205)
21. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
Drobyski WR; Majewski D; Hanson G
Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
[TBL] [Abstract][Full Text] [Related]
22. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
Johnson BD; Becker EE; Truitt RL
Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
[TBL] [Abstract][Full Text] [Related]
23. An absence of CCR5 on donor cells results in acceleration of acute graft-vs-host disease.
Welniak LA; Wang Z; Sun K; Kuziel W; Anver MR; Blazar BR; Murphy WJ
Exp Hematol; 2004 Mar; 32(3):318-24. PubMed ID: 15003318
[TBL] [Abstract][Full Text] [Related]
24. Inter-strain tissue-infiltrating T cell responses to minor histocompatibility antigens involved in graft-versus-host disease as determined by Vbeta spectratype analysis.
Zilberberg J; McElhaugh D; Gichuru LN; Korngold R; Friedman TM
J Immunol; 2008 Apr; 180(8):5352-9. PubMed ID: 18390717
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of T cell costimulation by VCAM-1 prevents murine graft-versus-host disease across minor histocompatibility barriers.
Schlegel PG; Vaysburd M; Chen Y; Butcher EC; Chao NJ
J Immunol; 1995 Oct; 155(8):3856-65. PubMed ID: 7561092
[TBL] [Abstract][Full Text] [Related]
26. Studies of immunologic tolerance to host minor histocompatibility antigens following allogeneic bone marrow transplantation in mice.
Perreault C; Allard A; Brochu S; Poupart C; Fontaine P; Bélanger R; Gyger M
Bone Marrow Transplant; 1990 Aug; 6(2):127-35. PubMed ID: 2145050
[TBL] [Abstract][Full Text] [Related]
27. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
[TBL] [Abstract][Full Text] [Related]
28. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS
J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345
[TBL] [Abstract][Full Text] [Related]
29. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease.
Schultz KR; Paquet J; Bader S; HayGlass KT
Bone Marrow Transplant; 1995 Aug; 16(2):289-95. PubMed ID: 7581150
[TBL] [Abstract][Full Text] [Related]
30. Tolerance to host minor histocompatibility antigens after allogenic bone marrow transplantation. Specific donor-host unresponsiveness is maintained by peripheral tolerizing cells.
Brochu S; Roy DC; Perreault C
J Immunol; 1992 Nov; 149(10):3135-41. PubMed ID: 1431092
[TBL] [Abstract][Full Text] [Related]
31. Different subsets of T cells in the adult mouse bone marrow and spleen induce or suppress acute graft-versus-host disease.
Palathumpat V; Dejbakhsh-Jones S; Holm B; Strober S
J Immunol; 1992 Aug; 149(3):808-17. PubMed ID: 1386094
[TBL] [Abstract][Full Text] [Related]
32. The role of TNF in hepatic histopathological manifestations and hepatic CD8+ T cell alloresponses in murine MHC class I disparate GVHD.
El-Hayek JM; Rogers TE; Brown GR
J Leukoc Biol; 2005 Oct; 78(4):1001-7. PubMed ID: 16081594
[TBL] [Abstract][Full Text] [Related]
33. Flow-microfluorometric monitoring of oligoclonal CD8+ T cell responses to an immunodominant Moloney leukemia virus-encoded epitope in vivo.
Brawand P; Biasi G; Horvath C; Cerottini JC; MacDonald HR
J Immunol; 1998 Feb; 160(4):1659-65. PubMed ID: 9469422
[TBL] [Abstract][Full Text] [Related]
34. Prevention of lethal graft-versus-host disease in mice by monoclonal antibodies directed against T cells or their subsets. I. Evidence for the induction of a state of tolerance based on suppression.
Knulst AC; Tibbe GJ; Noort WA; Bril-Bazuin C; Benner R; Savelkoul HF
Bone Marrow Transplant; 1994 Mar; 13(3):293-301. PubMed ID: 8199571
[TBL] [Abstract][Full Text] [Related]
35. Alloantigen recognition is critical for CD8 T cell-mediated graft anti-tumor activity against murine BCL1 lymphoma after myeloablative bone marrow transplantation.
Pillai A; Teo P; George T; Mukhopadhyay A; Dejbakhsh-Jones S; Strober S
Bone Marrow Transplant; 2007 Sep; 40(5):487-97. PubMed ID: 17603512
[TBL] [Abstract][Full Text] [Related]
36. Phenotypic analysis of donor cells infiltrating the small intestinal epithelium and spleen during graft-versus-host disease.
Schattenfroh NC; Hoffman RA; McCarthy SA; Simmons RL
Transplantation; 1995 Jan; 59(2):268-73. PubMed ID: 7839451
[TBL] [Abstract][Full Text] [Related]
37. Lethal graft-vs-host disease induced by a class II MHC antigen only disparity is not mediated by cytotoxic T cells.
Thiele DL; Bryde SE; Lipsky PE
J Immunol; 1988 Nov; 141(10):3377-82. PubMed ID: 3053897
[TBL] [Abstract][Full Text] [Related]
38. CD8+ cytotoxic T cell repertoire implicated in grafts-versus-leukemia effect in a murine bone marrow transplantation model.
de La Selle V; Riché N; Dorothé G; Bruley-Rosset M
Bone Marrow Transplant; 1999 May; 23(9):951-8. PubMed ID: 10338053
[TBL] [Abstract][Full Text] [Related]
39. Facilitation of parental-strain marrow engraftment by T cells of neonatally-tolerant mice.
Davenport C; George T; Devora GA; Morris MA; Gordon BE; Kumar V; Bennett M
Biol Blood Marrow Transplant; 1997 Dec; 3(6):294-303. PubMed ID: 9502296
[TBL] [Abstract][Full Text] [Related]
40. Protection from T helper cell-mediated graft-versus-host disease by the presence of an MHC class I alloantigen is associated with perturbation of MHC class II-restricted responses by class I-derived peptides.
Leibnitz RR; Lipsky PE; Thiele DL
J Immunol; 1995 Aug; 155(4):1784-95. PubMed ID: 7636234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
